Skeptics pounce after Bristol-Myers scores an early hit on Opdivo-Yervoy combo for lung cancer
Bristol-Myers Squibb’s closely watched study dubbed Checkmate-227 hit early, with researchers touting a success for their combination of Opdivo and Yervoy in treating frontline non-small cell lung cancer cases.
In a statement the company $BMY says that researchers tracked a “highly” significant progression-free survival rate for patients with a high tumor mutation burden (TMB), regardless of PD-L1 expression. Their combination was compared with chemo in the study, which is still tracking for overall survival results.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.